Non-compaction of the ventricular myocardium.

Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation (1990) 7.87

Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart (2001) 7.87

Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol (2000) 6.77

Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol (2005) 5.63

Isolated noncompaction of the myocardium in adults. Mayo Clin Proc (1997) 4.63

Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol (1999) 3.38

Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol (2003) 3.20

Identification of a rare congenital anomaly of the myocardium by two-dimensional echocardiography: persistence of isolated myocardial sinusoids. Am J Cardiol (1984) 2.48

Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr (2004) 2.36

Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation (2001) 2.24

Noncompaction of the ventricular myocardium. J Am Soc Echocardiogr (1999) 1.93

Postnatal persistence of spongy myocardium with embryonic blood supply. Arch Pathol (1975) 1.86

ANGIOGRAPHIC DEMONSTRATION OF INTRAMYOCARDIAL SINUSOIDS IN PULMONARY-VALVE ATRESIA WITH INTACT VENTRICULAR SEPTUM AND HYPOPLASTIC RIGHT VENTRICLE. N Engl J Med (1964) 1.68

Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet (1997) 1.55

Noncompaction of ventricular myocardium: CT appearance. AJR Am J Roentgenol (1991) 1.51

Myocardial ischaemia in children with isolated ventricular non-compaction. Eur Heart J (1999) 1.48

MRI of subendocardial perfusion deficits in isolated left ventricular noncompaction. J Comput Assist Tomogr (2002) 1.29

Isolated non-compaction of the left ventricle: a rare indication for transplantation. J Heart Lung Transplant (2001) 1.14

Noncompaction of the myocardium associated with Roifman syndrome. Cardiol Young (2001) 1.01

Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart (2001) 0.99

Left ventricular non-compaction in a patient with becker's muscular dystrophy. Heart (1996) 0.97

Histological appearance of left ventricular hypertrabeculation/noncompaction. Cardiology (2002) 0.91

Isolated noncompaction cardiomyopathy presenting with paroxysmal supraventricular tachycardia--case report and literature review. Angiology (2003) 0.91

Isolated noncompaction of the ventricular myocardium: contrast echocardiographic findings and review of the literature. Echocardiography (2002) 0.90

Isolated noncompaction of ventricular myocardium associated with fatal ventricular fibrillation. Pediatr Cardiol (2001) 0.88

Spongy left ventricular myocardium in an adult. Tex Heart Inst J (1998) 0.86

[Isolated non-compaction of the left ventricle]. Arch Mal Coeur Vaiss (2003) 0.83

Isolated noncompaction of the myocardium: multiplane transesophageal echocardiography diagnosis in an adult. J Am Soc Echocardiogr (2000) 0.81

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol (2006) 6.11

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 5.95

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol (2006) 5.81

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace (2006) 3.52

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace (2006) 3.11

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet (2009) 2.83

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71

Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J (2006) 2.54

Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005) 2.28

Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail (2011) 2.28

Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail (2008) 2.11

Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. Int J Cardiol (2013) 2.04

Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension. J Clin Hypertens (Greenwich) (2014) 2.02

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88

Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86

The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol (2013) 1.75

n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation (2011) 1.71

Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol (2013) 1.69

Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J (2003) 1.67

Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail (2013) 1.66

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J (2013) 1.65

Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol (2011) 1.64

The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther (2008) 1.63

Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail (2008) 1.63

Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol (2007) 1.58

International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail (2014) 1.58

A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol (2006) 1.57

Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol (2013) 1.55

Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail (2013) 1.53

Prospective assessment of integrating the existing emergency medical system with automated external defibrillators fully operated by volunteers and laypersons for out-of-hospital cardiac arrest: the Brescia Early Defibrillation Study (BEDS). Eur Heart J (2005) 1.52

Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology (2011) 1.51

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J (2013) 1.50

Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol (2002) 1.49

Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail (2008) 1.44

High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion. Intern Emerg Med (2009) 1.44

Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. J Cardiovasc Med (Hagerstown) (2006) 1.43

Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure　- Application of Metabolic Exercise Cardiac Kidney Indexes Score. Circ J (2015) 1.42

Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: role of peak oxygen consumption. Int J Cardiol (2013) 1.40

Acute myocardial infarction in a young woman with antiphospholipid syndrome and occasional cocaine abuse. Int J Cardiol (2005) 1.40

Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail (2005) 1.40

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J (2010) 1.39

[Plasma brain natriuretic peptide levels in the diagnostic and prognostic assessment of patients with heart failure. Pros]. Ital Heart J (2003) 1.38

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail (2008) 1.38

EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2013) 1.37

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol (2011) 1.34

Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep (2010) 1.33

EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2010) 1.32

Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail (2010) 1.27

Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol (2005) 1.27

Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail (2003) 1.25

Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res (2003) 1.21

The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J (2006) 1.20

The role of the kidney in heart failure. Eur Heart J (2012) 1.16

Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail (2011) 1.16

Design of the RELAXin in acute heart failure study. Am Heart J (2012) 1.15

The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail (2012) 1.14

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart (2007) 1.14

Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev (2008) 1.13

Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol (2003) 1.13

[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. Rev Port Cardiol (2007) 1.10

The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail (2007) 1.08

Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol (2009) 1.08

Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06

Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail (2012) 1.06

Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail (2012) 1.06

The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail (2004) 1.05

Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. Circulation (2003) 1.05

Percutaneous coronary angioplasty in a patient with anomalous single coronary artery arising from the right sinus of Valsalva. Int J Cardiol (2006) 1.05

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail (2013) 1.04

Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. Eur J Heart Fail (2009) 1.03

Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev (2014) 1.03

Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail (2013) 1.02

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev (2009) 1.02

Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J (2005) 1.01

Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation (2010) 1.00